MAINTENANCE OF ENDOMETRIOSIS-ASSOCIATED PAIN REDUCTION AND QUALITY OF LIFE IMPROVEMENT IN PHASE 3 EXTENSION STUDIES WITH ELAGOLIX.

被引：2
|
作者：
Taylor, H. S. [1 ]
Johnson, N. [2 ]
Carr, B. [3 ]
Leyland, N. [4 ]
Rechberger, T. [5 ]
Duan, W. R. [6 ]
Peloso, P. M. [6 ]
Soliman, A. M. [6 ]
Schwefel, B. [6 ]
Chwalisz, K. [6 ]
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia
[3] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[4] McMaster Univ, Hamilton, ON, Canada
[5] Med Univ Lublin, Lublin, Poland
[6] AbbVie, N Chicago, IL USA
来源：
FERTILITY AND STERILITY | 2017年 / 108卷 / 03期
关键词：
D O I：
10.1016/j.fertnstert.2017.07.294
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
O-234
引用
收藏
页码：E96 / E97
页数：2
相关论文
共 50 条
  • [41] Once Daily Oral Relugolix Combination Therapy Versus Placebo in Patients With Endometriosis-Associated Pain: Two Replicate Phase 3, Randomised, Double-Blind, Studies (SPIRIT 1 and 2)
    Adams, Ellise D.
    JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING, 2024, 53 (06): : 590 - 593
  • [42] Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis
    Panes, J.
    Rubin, D. T.
    Vermeire, S.
    Lindsay, J. O.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S315 - S317
  • [43] MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Panes, J.
    Rubin, D. T.
    Vermeire, S.
    Lindsay, J. O.
    Sands, B. E.
    Su, C.
    Friedman, G.
    Zhang, H.
    Kayhan, C.
    Manuchehri, A.
    Healey, P.
    GUT, 2017, 66 : A121 - A122
  • [44] MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Panes, Julian
    Rubin, David T.
    Vermeire, Severine
    Lindsay, James O.
    Sands, Bruce E.
    Su, Chinyu
    Friedman, Gary
    Zhang, Haiying
    Kayhan, Cem
    Manuchehri, Alireza
    Healey, Paul J.
    GASTROENTEROLOGY, 2017, 152 (05) : S601 - S602
  • [45] Prolonged Medical Cannabis Treatment is Associated With Quality of Life Improvement and Reduction of Analgesic Medication Consumption in Chronic Pain Patients
    Aviram, Joshua
    Lewitus, Gil M.
    Vysotski, Yelena
    Yellin, Ben
    Berman, Paula
    Shapira, Anna
    Meiri, David
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [46] EFFICACY AND SAFETY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (SPIRIT 2).
    As-Sanie, Sawsan
    Becker, Christian M.
    Johnson, Neil
    Lessey, Bruce Arthur
    Abrao, Mauricio S.
    Brown, Eric L.
    Wilk, Krzysztof
    Ferreira, Juan Camilo Arjona
    Mathur, Vandana
    Li, Yulan
    Warsi, Qurratul Ann
    Wagman, Rachel B.
    Giudice, Linda C.
    FERTILITY AND STERILITY, 2020, 114 (03) : E77 - E77
  • [47] LONG-TERM ELAGOLIX plus ADD-BACK THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN FOR 48 MONTHS+12 MONTH POST-TREATMENT FOLLOW-UP: A SAFETY UPDATE ON BONE MINERAL DENSITY DATA OF A PHASE 3 STUDY.
    Simon, James A.
    Kim, Jin Hee
    Thomas, James W.
    Miller, Charles E.
    Chan, Anna
    Snabes, Michael C.
    FERTILITY AND STERILITY, 2024, 122 (04) : E157 - E157
  • [48] BIMEKIZUMAB IS ASSOCIATED WITH IMPROVEMENT IN QUALITY OF LIFE IN PATIENTS ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS AT WEEK 16: RESULTS FROM TWO PHASE 3 STUDIES
    McKay, Neil
    Bennett, Alexander
    Goodson, Nicola
    Fleurinck, Carmen
    de la Loge, Christine
    Massow, Ute
    Taieb, Vanessa
    Marzo-Ortega, Helena
    Gaffney, Karl
    RHEUMATOLOGY, 2023, 62
  • [49] Secukinumab is associated with sustained improvement in patients' quality of life up to year 5: results of a randomized extension of the phase III erasure and fixture trials
    Langley, R.
    Sigurgeirsson, B.
    Szepietowski, J.
    Tsai, T-F.
    de Vera, A.
    Charef, P.
    Gilloteau, I.
    You, R.
    Hampele, I.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 78 - 78
  • [50] Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study
    Harada, Tasuku
    Osuga, Yutaka
    Suzuki, Yusuke
    Fujisawa, Masaki
    Fukui, Motoko
    Kitawaki, Jo
    FERTILITY AND STERILITY, 2022, 117 (03) : 583 - 592
12345